Immunome Expects Its Three-antibody Cocktail IMM-BCP-01 To Neutralize Omicron Variant; Stock Up 18%

Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529).

Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern, Immunome expects its three-antibody cocktail, IMM-BCP-01, to neutralize the Omicron variant.

The Omicron variant has a number of mutations across the ACE2 receptor binding site. IMM-BCP-01 is an antibody cocktail designed to target three distinct, non-overlapping epitopes. Two of IMM-BCP-01's three antibodies target epitopes outside of the ACE2 receptor binding site.

The Company is diligently working to confirm this activity in laboratory testing and expects initial results to be available in January 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT